What is PSA?
PSA is an androgen-regulated serine protease, an enzyme, secreted exclusively by prostate glandular epithelial cells and to a greater extent secreted by prostate cancer cells. The PSA enzyme is largely confined within normal prostate glands and is secreted into the ejaculatory ducts to liquify viscus semen. However, in cancer, increasingly so when the Gleason pattern is 4 or more, the confining walls of the malignant prostate glands are fractured, and the PSA enters the blood stream.
PSA is not specific for prostate cancer. When the PSA is low, i.e., <4 ng/mL., the amount of PSA secreted from malignancy overlaps with the noncancerous levels of PSA. This is exampled clearly in the work of Ian M. Thompson, et al. “Prevalence of Prostate Cancer among Men with Prostate Specific Antigen level < 4.0 ng per Milliliter.” NEJM. 2004. Thompson made the point “that PSA is not highly specific [for prostate cancer] even at relatively low level.” Elevations of PSA occur normally with large glands BPH (Benign Prostatic Hypertrophy), prostatitis and PSA increases with age.
Their study of 2950 men, biopsied when their PSAs were < 4.0 ng/mL, showed the following relationship between PSA levels and the detection of cancer.
- When the total PSA was <5 ng/mL prostate cancer was detected in 6.6% of men.
- 1% of men showed cancer with a PSA level of 0.6 – 1.0 ng/mL.
- 17% with PSAs between 1.1 to 2.0.
- When the PSA was between 1 – 3.0, cancer was detected at 23.9%; and at PSA between 3.1 – 4.0, 26.9%.
The author’s conclusion was that there is no PSA value below which prostate cancer risk is zero.
Although 14.9% of the men in the study men had Gleason Score > 7 cancers, the majority were low grade, Gleason 6, and would likely have undergone Active Surveillance. Among those men with high Gleason scores, those with a PSA velocity of greater > 2.0 ng/mL in one year would be identified as warranting immediate treatment because that rate of increase confers a 10-fold greater risk of death, based on a study by D’Amico et al., “Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy,” NEJM 2004.
The important point underlying these observations is that the goal is not necessarily to discover that a man has cancer but to restrict discovery to those men who need treatment.
Prostate Cancer Can be Diagnosed by Analysis of Urine.
1. Already available are programs which, while not specifically diagnosing cancer, give guidance as to whom should be biopsied and treated. The most validated of these urine tests is MPS2, an 18-gene test which detects Grade Group >=2 cancers on home-collected urine. No rectal exam required. Example: Tosoian et al., reports “Clinical Validation of MYProstateScore 2.0 Using First-Catch, Non-Digital Rectal Examination Urine.” MPS2 detected “ >90% of Grade Group > 2 cancers and “would have avoided 36% to 42% of unnecessary biopsies.” (To access the test go to MPS2.com)
2, Under development is a ”Urine-Based Machine Learning Assay [that] Detects Prostate Cancer,” Hausman et al., 2026. The test ”captures disease-specific biochemical signatures” by analyzing urine that has been placed on a prepared slide, a platform termed the PanGIA Analysis System (PAS) (PanGIA Biotech Inc.) The assay achieved a 97.8 % sensitivity and 53% specificity for prostate cancer across all grades compared to PSA – sensitivity 80% and 20% to 40% specificity. “PAS aims to minimize unnecessary biopsies. … and offers a simple, non-invasive means to detect cancer early when it is most treatable.”
BOTTOM LINE:
While PSA remains valuable for following treatment outcome, its role as a diagnostic tool is being challenged by analysis of urine.